Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONCY $0.90 0.0799 +9.74%
SGEN $38.05 2.8000 +7.94%
IMGN $9.98 0.4900 +5.16%
CLSN $2.88 0.1300 +4.73%
INCY $66.70 2.5200 +3.93%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CERU $4.25 -0.5110 -10.74%
GLYC $6.75 -0.2500 -3.57%
OMED $21.74 -0.4100 -1.85%
CTIC $2.35 -0.0359 -1.50%
FPRX $13.32 -0.1150 -0.86%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Castle Biosciences’ Multi-Analyte Test Successfully Identifies Esophageal Cancer Patients Who Are Extremely Resistant to Standard Treatment of Chemoradiation Therapy

(Yahoo! Finance) Oct 23, 2014 - Castle Biosciences Inc. today announced that results from a second validation study of its proprietary multi-analyte test, DecisionDx-EC, confirmed the test’s ability to identify which esophageal cancer patients are unlikely to benefit from the standard pre-surgical treatment of chemoradiation.
read article 



Data Presented at the International Society of Paediatric Oncology (SIOP) Congress Show Palonosetron Is a Valuable Option For Treating Pediatric Patients Receiving Moderately to Highly Emetogenic Chemotherapy

(Yahoo! Finance) Oct 23, 2014 - Helsinn Group, the company focused on building quality cancer care, presented data at the International Society of Paediatric Oncology (SIOP) congress establishing that palonosetron, at a dose 20 g/kg, is a valuable and efficacious treatment option for chemotherapy-induced nausea and vomiting (CINV) in pediatric patients up to 17 years of age.
read article 



Wait on Radiation After Surgery For Glioblastoma

(Medscape Medical News) Oct 22, 2014 - Patients with newly diagnosed glioblastoma multiforme (GBM) have significantly better overall survival when there is a short delay between surgery and the start of radiation therapy, investigators say.
read article (free registration required) 



Experimental Breast Cancer Drug Holds Promise in Combination Therapy For Ewing Sarcoma

(St. Jude) Oct 23, 2014 - Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. Jude Children’s Research Hospital scientists.
read press release 



New Evidence That Colonoscopy Reduces Cancer Risk, Mortality

(Medscape Medical News) Oct 23, 2014 - Colonoscopy reduces cancer risk and mortality in patients with inflammatory bowel disease, according to the largest study of its kind, presented here at the American College of Gastroenterology (ACG) 2014 Annual Scientific Meeting.
read article (free registration required) 



How Medicare ‘Self-Referral’ Thrives on Loophole

(Wall Street Journal) Oct 22, 2014 - In a letter to a friend, the manager of a Florida urology practice worried in 2010 that her company would attract federal scrutiny for its frequent use of an expensive bladder-cancer test.
read article (paid subscription required) 



Johnson & Johnson Accelerates Ebola Vaccine Testing Amid Heightened Anxiety

(NJ.com/NJ Advance Media) Oct 22, 2014 - Johnson & Johnson announced Wednesday it will ramp up its testing of an Ebola vaccine.
read article 



Roche Plans $3.2 Billion of Property Investment in Basel

(Bloomberg) Oct 22, 2014 - Roche Holding AG plans to invest 3 billion Swiss francs ($3.2 billion) at its Basel headquarters over the next decade as the world’s biggest maker of cancer drugs updates its research and office facilities.
read article 



FDA Panel Recommends Expanded Approval of CF Drug

(Wall Street Journal) Oct 21, 2014 - A Food and Drug Administration advisory committee has recommended approval of Vertex Pharmaceuticals Inc.’s cystic fibrosis drug to patients age 6 and older with the R117H mutation.
read article (paid subscription required) 



Biogen Falls After Patient on Top-Selling Drug Dies

(Bloomberg) Oct 22, 2014 - Shares of Biogen Idec Inc. fell as much as 11 percent after the company said a patient developed a rare brain infection and died while taking its top-selling multiple sclerosis drug Tecfidera.
read article 



Third Point's Loeb Urges Breakup of Biotech Company Amgen

(Reuters) Oct 21, 2014 - Hedge fund manager Daniel Loeb told investors on Tuesday he urged U.S. biotechnology company Amgen Inc to split into two separate businesses, a move he said could boost its share price by more than 80 percent.
read article 



Dimon Says 'Terrifying' Cancer Hasn't Changed His JPMorgan Plans

(Bloomberg) Oct 22, 2014 - JPMorgan Chase & Co. Chief Executive Officer Jamie Dimon said cancer hasn’t altered his plans to keep working even as he looks toward a retirement that he hopes will include philanthropy and teaching.
read article 



SAMFund Battles Financial Side Effects of Cancer

(Boston Business Journal/Healthcare Inc. blog) Oct 22, 2014 - The health care system did little to help Watson in battling another ugly, devastating side effect of cancer – the financial burden.
read article 



The Next Generation Of Cancer Research Will Be Patient-Centered

(Forbes) Oct 22, 2014 - The issues facing patients and survivors go far beyond the medical impact of the disease.
read article 



Cancer Centers Often Fall Short on Providing Useful Info, A Study Finds

(Washington Post/Consumer Reports) Oct 21, 2014 - According to a study by the University of Pittsburgh Medical Center, advertisements for cancer centers are too often long on emotion and short on realistic and useful information.
read article (free registration required) 



Exact Sciences CEO Has High Hopes for At-Home Cancer Test

(Wall Street Journal/Boss Talk) Oct 21, 2014 - The week that Kevin T. Conroy took over as CEO of Exact Sciences Corp. in 2009, the molecular-diagnostics company got a warning from the Nasdaq that it faced delisting if its market capitalization didn’t improve. Its efforts to develop a noninvasive test for colon cancer had stalled and its stock was trading at around $1.
read article (paid subscription required) 



Exact Sciences Announces MDVIP As The First Network of Personalized Healthcare Physicians To Offer Cologuard, A New Noninvasive Stool-Based DNA Test For Colon Cancer

(Yahoo! Finance) Oct 22, 2014 - MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through their physicians.
read article 



Horizon Blue Cross Blue Shield of New Jersey Creates Ground-breaking Patient-centered Program for Cancer Treatment

(PRWeb) Oct 21, 2014 – Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) announced today that it has joined with Regional Cancer Care Associates (RCCA) – one of the nation’s largest oncologist physician groups – to create an Episode of Care (EOC) program to deliver highly specialized care for breast cancer patients.
read press release 



Astellas Announces Revision of Package Insert in Japan for XTANDI® (enzalutamide) Capsules, a Prostate Cancer Treatment

(Astellas) Oct 22, 2014 – Astellas Pharma Inc. announced the revision of the package insert for the oral androgen receptor signaling inhibitor XTANDI® Capsules 40mg (generic name: enzalutamide, “XTANDI”).
read corporate press release 



FDA Adds Everolimus to Watch List

(Medscape Medical News) Oct 21, 2014 - Signal for possible hypertension risk leads FDA to add the kidney cancer and transplant drug everolimus to its watch list.
read article (free registration required) 



Findings Point to an 'Off Switch' for Drug Resistance in Cancer

(Salk Institute) Oct 20, 2014 - Scientists at the Salk Institute have uncovered details about how cancer is able to become drug resistant over time, a phenomenon that occurs because cancer cells within the same tumor aren’t identical–the cells have slight genetic variation, or diversity.
read press release 



Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology

(Rutgers Today/Rutgers University) Oct 21, 2014 - A new medical imaging method being developed at Rutgers University could help physicians detect cancer and other diseases earlier than before, speeding treatment and reducing the need for invasive, time-consuming biopsies.
read article 



Scientists Discover Hidden Subpopulation of Melanoma Cells

(UNC Health Care) Oct 22, 2014 - UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors.
read press release 



Loss of Y Chromosome Associated with Higher Mortality and Cancer in Men

(ASHG) Oct 21, 2014 - Age-related loss of the Y chromosome (LOY) from blood cells, a frequent occurrence among elderly men, is associated with elevated risk of various cancers and earlier death, according to research presented at the American Society of Human Genetics (ASHG) 2014 Annual Meeting in San Diego.
read press release 



Fecal Blood Test May Save More Lives Than Colonoscopy

(Center for Advancing Health/HBNS) Oct 21, 2014 - State public health programs could screen many more low-income and uninsured people for colorectal cancer – and save up to four times as many lives – by using stool sample blood tests instead of colonoscopies, finds a new study in Health Services Research.
read press release